Wedel, Germany (01/04/2024) medac GmbH is proud to announce its support for an upcoming hybrid symposium titled "Optimizing Outcomes for Patients With NMIBC - Challenges and Recent Developments in Clinical Practice." The symposium will take place on April 6th, 2024, at Paris Expo Porte de Versailles, in the Purple Area, Room S01, and can also be joined online via www.medscape.org/symposium/nmibc.
Chaired by Dr. Alexandra Masson-Lecomte, Professor of Urology at the Saint-Louis Hospital, APHP and University Paris Cite, the symposium will feature esteemed panelists including:
Ashish M. Kamat, MD, MBBS
Professor of Urology and Cancer Research
The University of Texas
MD Anderson Cancer Center
Houston, Texas, United States.
Laura S. Mertens, MD, PhD, FEBU
Urologist
Department of Urology
Netherlands Cancer Institute
Amsterdam, the Netherlands
The interactive, case-based symposium will address the challenges faced by patients with NMIBC, provide insights into current risk assessment recommendations, and explore therapeutic treatment strategies for different patient populations. Attendees will have the opportunity to participate in discussions and submit questions to be addressed by the expert panelists throughout the program. It is tailored for urologists, oncologists, and other members of oncology care teams in Europe involved in the management of patients with non-muscle invasive bladder cancer (NMIBC).
The symposium has been accredited by the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM), offering attendees 1.0 continuing professional development credits (CPD).
For more information and to register for the symposium, please visit this link: www.medscape.org/symposium/nmibc.
